Haemoglobin-based oxygen carriers and myocardial infarction

Figures & data

Table 1. Incidence of myocardial infarction in phase II and III clinical trials of HBOCs and potential correlating parameters^a.

HBOC	MI incidence (#/# patients)		MI ratio	Avg Mol	Estimated	Radius of gyration
	Treated	Controls	%Treated/%controls	Wt (kD)	Avg. dose (g/kg)	(nm)
Hemospan	6/249	1/222	5.3	95	0.2	9.3
HemAssist	8/456	5/454	1.6	65	0.7	3.1
Hemolink	14/206	7/213	2.1	156	1.1	4.9
Hemopure	14/797	4/661	2.9	250	1.7	6.4 (est.)
Polyheme	21/451	3/459	7.1	300	3.1	7.9 (est.)
Total or Avg	63/2159	20/2009	2.9 (Avg)	NA	NA	NA

^a See text for HBOC data references and methods for determining average dose and radius of gyration.

Figure 1. Relative incidence of myocardial infarction as a function of average HBOC dose: crosslinked and/or polymerized HBOCs (Δ) and PEG modified HBOC (■).

Figure 2. Relative incidence of myocardial infarction as a function of average HBOC size: crosslinked and/or polymerized HBOCs (Δ) and PEG modified HBOC (■).